Table 3.
Oral medications at hospital discharge and in outpatients with chronic heart failure
| HHF | CHF | P‐value | |
|---|---|---|---|
| ACE/ARBs, % | 85.8 | 89.8 | <0.0001 |
| Beta blockers, % | 65.8 | 67.0 | 0.252 |
| MRAs, % | 68.2 | 86.4 | <0.0001 |
| Diuretics, % | 93.0 | 84.9 | <0.0001 |
| Digitalis, % | 36.1 | 47.0 | <0.0001 |
| Statins, % | 71.5 | 50.9 | <0.0001 |
| Anti‐platelets, % | 79.7 | 58.2 | <0.0001 |
| Nitrates, % | 51.7 | 41.0 | <0.0001 |
| CCBs, % | 8.4 | 5.4 | 0.017 |
| Anticoagulants, % | 30.7 | 30.0 | 0.962 |
| Amiodarone, % | 10.7 | 10.8 | 0.868 |
| Ivabradine, % | 6.4 | 20.4 | <0.0001 |
ACE, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; CCBs: calcium channel blockers; CHF, chronic heart failure patients; HHF, hospitalized heart failure patients; MRAs, mineraloreceptor antagonists.